Clinical Research Focused on Benefiting Patients With Movement Disorders

University Hospitals Neurological Institute’s Parkinson’s & Movement Disorders Center is using clinical research to quickly bring advances from the laboratory to the bedside.

Along with Case Western Reserve University School of Medicine, the center is working to refine current techniques and discover new treatments. Areas of investigation include:

  • The establishment of the Case Western Reserve University Clinical and Translational Science Collaborative’s (CTSC) Parkinson’s disease phenotypic and genotypic registry to examine the genetic effects of the disease.
  • Participation in the national BrainGate 2 study, which is examining the potential and ability of those suffering paralysis to control a computer cursor and other assistive devices with their thoughts.
  • A Phase 4, open-label, efficacy and safety study of APOKYN® for rapid and reliable improvement of motor symptoms in Parkinson’s disease.
  • A National Institutes of Health-sponsored study examining functional magnetic resonance imaging (fMRI) investigations of the effects of deep brain stimulation in dystonia.
  • Functional magnetic resonance imaging (fMRI) investigations of Parkinson’s disease and the brain network changes involved in changes in the handling and perception of other parts of the body for patients with Parkinson’s disease.

IMPAX 3 trial for patients with Parkinson’s Disease and motor fluctuations

We are currently enrolling in the IMPAX 3 trial (“A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS”). This is a study evaluating the safety and efficacy of IPX203 as compared to immediate release carbidopa-levodopa in patients with Parkinson’s disease who have motor fluctuations. The study will consist of a three-week open label carbidopa-levodopa dose adjustment period, a four-week open label period for conversion to IPX203, and then a 13-week double blind, randomized treatment period to one drug or the other. The study will enroll approximately 510 and randomize 420 subjects.

You may qualify for this study if:

  • You are 40 years or older and diagnosed with Parkinson’s disease
  • You are on a stable regimen of carbidopa-levodopa and responding well to the treatment
  • You have not had neurosurgical treatment for Parkinson’s disease

Request more information

SURE PD3 for patients with early

Study of Urate Elevation in Parkinson’s Disease, Phase 3

This study is not currently enrolling, but several patients are actively participating at University Hospitals and across the country.

Back to Top